A Bayesian phase I/ <scp>II</scp> design to determine <scp>subgroup‐specific</scp> optimal dose for immunotherapy sequentially combined with radiotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Bayesian phase I/ II design to determine subgroup‐specific optimal dose for immunotherapy sequentially combined with radiotherapy

Published:2022-09-26 Issue:1 Volume:22 Page:143-161
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Guo Beibei¹^ORCID,Zang Yong²³,Lin Li‐Hsiang¹,Zhang Rui⁴⁵

Affiliation:

1. Department of Experimental Statistics Louisiana State University Baton Rouge Louisiana USA

2. Department of Biostatistics and Data Science School of Medicine, Indiana University Indianapolis Indiana USA

3. Center for Computational Biology and Bioinformatics Indiana University Indianapolis Indiana USA

4. Department of Physics and Astronomy Louisiana State University Baton Rouge Louisiana USA

5. Department of Radiation Oncology Mary Bird Perkins Cancer Center Baton Rouge Louisiana USA

Funder

Louisiana Board of Regents

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2265

Reference38 articles.

1. A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

2. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer

3. Personalizing immunotherapy balancing predictability and precision;Agur Z;Onco Targets Ther,2012

4. Personalized immunotherapy in cancer precision medicine

5. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies;Clinical Trials;2024-01-11

2. Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy;Biometrical Journal;2023-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3